Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH)
Evidence Rating Level: 1 (Excellent)
Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease...
1. Based on this meta-analysis of available randomized controlled trials (RCTs), use of thiazolidinediones in patients with non-alcoholic steatohepatitis (NASH) demonstrated regression of liver fibrosis. The observed effect was largely attributed to pioglitazone rather than rosiglitazone.
2. The improvement in liver fibrosis was observed in patients with and without diabetes.
1. Delivery of a hybridized form of glucagon and the thyroid hormone T3 (G/T3) improved signs of metabolic syndromes including dyslipidemia and nonalcoholic steatohepatitis (NASH).
2. Unlike treatment with T3 alone, G/T3 improved pathological signs without causing adverse effects on cardiac function and bone integrity.
Evidence Rating Level: 1 (Excellent) ...